Medicago has obtained a grant from the Quebec Ministry of Economic Development, Innovation and Export Trade to finance 40% of the study. The study will be conducted by SNC Lavalin with the assistance of Medicago and the Genopole d’Evry.
Andy Sheldon, president and CEO of Medicago, said: “As we are able to rapidly produce new vaccines in large quantities, we have been in discussions with several countries in Europe, Asia and Africa for the establishment of partnerships to create domestic vaccine production infrastructures based on Medicago’s technologies.”